Early detection is the single most decisive factor in cancer outcomes.
The Science
Circulating Tumour Cell Detection
TruCheck™ Intelli detects actual cancer cells released into the bloodstream by solid organ tumours. Using immunocytochemistry, the test determines not only their presence but their organ of origin. A single blood draw screens for cancers across more than 70 solid organ types.
Your Journey
The Experience
Step 01
Private Consultation
Your physician reviews your medical history and discusses the screening in full detail.
Step 02
Simple Blood Draw
A small sample is taken at our Harley Street clinic — or at your preferred location.
Step 03
Laboratory Analysis
Your sample is analysed at a leading UK laboratory using advanced immunocytochemistry.
Step 04
Results & Pathway
Findings are returned within 2–3 weeks. A clear pathway forward is outlined if needed.
Clinical Evidence
Precision & Confidence
88%
Sensitivity
Correctly identifies early-stage cancer in at least 88 of every 100 individuals. Meaningful findings are not missed.
99%
Specificity
Only 1 in 100 results may return a false positive, minimising unnecessary procedures and providing genuine peace of mind.
Comprehensive Coverage
What We Screen
The test covers a comprehensive range of solid organ cancers including melanoma, breast, lung, prostate, liver, thyroid, gastrointestinal, gynaecological, urinary tract, central nervous system, soft tissue sarcomas, and many more.
A positive result identifies the tissue of origin, enabling rapid and targeted intervention.
Solid Organ
Cancer Types
Important Details
Eligibility
Who
Individuals aged 40 and above with no current symptoms, prior diagnosis, or previous cancer treatment. Those aged 35–40 may be accepted where elevated risk factors are identified.
Frequency
We recommend annual screening as part of a comprehensive health assessment. The test is non-invasive, with no disadvantage to regular testing.